KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares Repurchased
Ratios

Emergent BioSolutions (EBS) Short-Term Debt repayments (2019 - 2024)

Historic Short-Term Debt repayments for Emergent BioSolutions (EBS) over the last 4 years, with Q3 2024 value amounting to $222.7 million.

  • Emergent BioSolutions' Short-Term Debt repayments rose 47102.56% to $222.7 million in Q3 2024 from the same period last year, while for Jun 2025 it was $222.7 million, marking a year-over-year increase of 9795.56%. This contributed to the annual value of $284.2 million for FY2024, which is 2873.62% down from last year.
  • Emergent BioSolutions' Short-Term Debt repayments amounted to $222.7 million in Q3 2024, which was up 47102.56% from $56.5 million recorded in Q2 2024.
  • In the past 5 years, Emergent BioSolutions' Short-Term Debt repayments ranged from a high of $353.0 million in Q3 2020 and a low of $5.0 million during Q1 2024
  • For the 3-year period, Emergent BioSolutions' Short-Term Debt repayments averaged around $132.0 million, with its median value being $47.8 million (2023).
  • As far as peak fluctuations go, Emergent BioSolutions' Short-Term Debt repayments soared by 225333.33% in 2020, and later crashed by 8375.5% in 2024.
  • Emergent BioSolutions' Short-Term Debt repayments (Quarter) stood at $353.0 million in 2020, then plummeted by 96.6% to $12.0 million in 2023, then surged by 1755.83% to $222.7 million in 2024.
  • Its last three reported values are $222.7 million in Q3 2024, $56.5 million for Q2 2024, and $5.0 million during Q1 2024.